Recent 8-K filings for CLDX

• May 7, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Celldex completes Phase 3 CSU enrollment 6 months early; raises $345M; Q1 net loss $78.7M

  Phase 3 CSU (EMBARQ-CSU1/2) enrolled 1,939 patients, 6 months ahead of guidance; topline data expected Q4 2026, BLA in 2027.

• April 2, 2026, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements

  Celldex prices $300M public offering of 10.3M shares at $29.00 for pipeline and barzolvolimab launch

  Priced underwritten public offering of 10,345,000 shares at $29.00/share; gross proceeds ~$300M.

• February 25, 2026, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Celldex completes Phase 3 CSU enrollment six months early; cash $518.6M; net loss $1.22/sh Q4

  Phase 3 CSU program enrolled 1,939 patients across 43 countries; topline data expected Q4 2026, BLA filing planned 2027.

• November 10, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Celldex Q3 net loss $67M; barzolvolimab Phase 2 data positive in urticarias

  Net loss of $67.0M ($1.01/share) vs $42.1M in Q3 2024; cash use $48.6M in operations.

• August 19, 2025, 7:59 PM ET other material materiality 0.75 negative item 8.01item 9.01

  Celldex Phase 2 barzolvolimab in EoE meets primary endpoint but no clinical benefit; advancement stopped

  Primary endpoint met: peak mast cell count reduced by -36.0 vs placebo -2.7 (p<0.0001) at Week 12.

• August 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Celldex Q2 net loss $56.6M ($0.85/share); cash $630.3M; barzolvolimab shows durable complete response at 76 weeks

  Net loss of $56.6M versus $35.8M in Q2 2024; R&D spend rose to $54.2M on barzolvolimab trials.

• June 6, 2025, 7:59 PM ET leadership materiality 0.50 neutral item 5.02item 5.07item 9.01

  Celldex shareholders approve equity plan increase, elect directors including Denice Torres

  Stockholders approved 2M share increase to 2021 Omnibus Plan (total 9.5M shares) with 53.2M for, 963K against.

• May 8, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Celldex Q1 net loss widens to $53.8M; Phase 3 CSU enrollment ongoing, multiple data readouts in 2025

  Net loss of $53.8M ($0.81/share) vs $32.8M ($0.56/share) in Q1 2024; R&D expenses rose to $52.6M.

• February 27, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Celldex reports Q4 2024 net loss of $47.1M; cash $725.3M; Phase 3 CSU studies enrolling

  Cash, equivalents and securities $725.3M at Dec 31, 2024; company funded through 2027.

• November 6, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Celldex Q3 net loss $42.1M; barzolvolimab meets Phase 2 CIndU endpoints

  Net loss of $42.1M ($0.64 per share) vs $38.3M in Q3 2023; revenue $3.2M vs $1.5M.

• August 8, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Celldex Q2 net loss $0.54 per share; Phase 3 CSU program launched

  Net loss $35.8M ($0.54/share) vs $30.5M loss in Q2 2023; revenue $2.5M, up from $0.3M.

• June 14, 2024, 7:59 PM ET other material materiality 0.40 neutral item 5.02item 5.07item 9.01

  Celldex shareholders approve 3.2M share increase to equity plan; director award limits raised

  Stockholders approved amendment increasing share reserve from 4.3M to 7.5M shares under 2021 Omnibus Plan.

• May 6, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Celldex reports Q1 net loss $32.8M; cash $823.8M; Phase 3 CSU studies planned summer 2024

  Net loss of $32.8M ($0.56 per share) vs $29.4M ($0.62) in Q1 2023; revenue $0.2M.

• March 1, 2024, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements

  Celldex prices upsized $400M common stock offering at $47/share, net proceeds ~$376M

  Priced public offering of 8,520,000 shares at $47.00 per share; upsized from initial $250M to $400M.

• February 26, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Celldex Q4 2023 net loss $43.3M; cash $423.6M; Phase 3 CSU study planned for summer 2024

  Q4 2023 net loss $43.3M ($0.83/share) vs $26.5M ($0.56) in Q4 2022; FY net loss $141.4M ($2.92/share).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event earnings

6 positive 1 negative 8 neutral

source · CLDX on sec.gov